Anixa Biosciences annual free cash flow
2010
2011
2012
2014
2015
2016
2017
2018
2019
2020
Anixa Biosciences Free Cash Flow (FCF) History (ANIX)
Anixa Biosciences reported −$6.2M in free cash flow for fiscal 2020, a decrease of $1.3M from the previous fiscal year.
View full Anixa Biosciences company overviewAnixa Biosciences free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2020 | 2020-10-31 | −$6.2M | −$1.3M | — | — |
| 2019 | 2019-10-31 | −$4.9M | −$605,079 | — | −1966.75% |
| 2018 | 2018-10-31 | −$4.3M | −$484,906 | — | −387.58% |
| 2017 | 2017-10-31 | −$3.8M | −$298,678 | — | −1055.70% |
| 2016 | 2016-10-31 | −$3.5M | −$4.8M | — | −1176.07% |
| 2015 | 2015-10-31 | $1.3M | $3.7M | — | +14.14% |
| 2014 | 2014-10-31 | −$2.4M | $756,403 | — | −65.06% |
| 2012 | 2012-10-31 | −$3.1M | −$2.4M | — | −334.29% |
| 2011 | 2011-10-31 | −$725,028 | $1.7M | — | −72.27% |
| 2010 | 2010-10-31 | −$2.4M | — | — | −329.54% |
Anixa Biosciences quarterly free cash flow
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2020 | 2020-10-31 | −$1.4M | −$773,987 | — | — |
| Q3 2020 | 2020-07-31 | −$1.3M | −$263,435 | — | — |
| Q2 2020 | 2020-04-30 | −$1.6M | −$366,229 | — | — |
| Q1 2020 | 2020-01-31 | −$1.9M | −$1.2M | — | — |
| Q3 2019 | 2019-07-31 | −$640,095 | $702,416 | — | — |
| Q4 2018 | 2018-10-31 | −$1.0M | −$274,909 | — | — |
| Q3 2018 | 2018-07-31 | −$1.2M | $63,904 | — | −328.28% |
| Q2 2018 | 2018-04-30 | −$751,783 | $324,576 | — | −100.24% |
| Q1 2018 | 2018-01-31 | −$1.3M | −$598,477 | — | — |
| Q4 2017 | 2017-10-31 | −$752,591 | −$67,726 | — | — |
| Q3 2017 | 2017-07-31 | −$1.3M | −$435,688 | — | −345.91% |
| Q2 2017 | 2017-04-30 | −$1.1M | $310,377 | — | — |
| Q1 2017 | 2017-01-31 | −$744,034 | −$105,641 | — | — |
| Q4 2016 | 2016-10-31 | −$684,865 | $117,060 | — | — |
| Q3 2016 | 2016-07-31 | −$818,226 | −$109,678 | — | −818.23% |
| Q2 2016 | 2016-04-30 | −$1.4M | $392,518 | — | — |
| Q1 2016 | 2016-01-31 | −$638,393 | −$5.2M | — | — |
| Q4 2015 | 2015-10-31 | −$801,925 | $38,834 | — | — |
| Q3 2015 | 2015-07-31 | −$708,548 | $205,930 | — | −745.84% |
| Q2 2015 | 2015-04-30 | −$1.8M | −$886,779 | — | −7117.02% |
| Q1 2015 | 2015-01-31 | $4.6M | $5.6M | — | +50.34% |
| Q3 2013 | 2013-07-31 | −$840,759 | −$212,321 | — | — |
| Q2 2013 | 2013-04-30 | −$914,478 | −$21,118 | — | — |
| Q1 2013 | 2013-01-31 | −$892,475 | −$234,368 | — | −41900.23% |
| Q4 2012 | 2012-10-31 | −$962,443 | −$249,953 | — | — |
| Q3 2012 | 2012-07-31 | −$628,438 | −$2.0M | — | −251.91% |
| Q2 2012 | 2012-04-30 | −$893,360 | −$165,081 | — | −360.12% |
| Q1 2012 | 2012-01-31 | −$658,107 | −$42,212 | — | −146.51% |
| Q4 2011 | 2011-10-31 | −$712,490 | — | — | −158.70% |
| Q3 2011 | 2011-07-31 | $1.3M | — | — | +295.68% |
| Q2 2011 | 2011-04-30 | −$728,279 | — | — | −837.92% |
| Q1 2011 | 2011-01-31 | −$615,895 | — | — | −3631.88% |
Anixa Biosciences free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $1.3M to −$6.2M, a net decrease of $7.5M. Anixa Biosciences's latest reported quarter, Q4 2020, generated −$1.4M in free cash flow, a decrease of $773,987 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Anixa Biosciences filings at SEC.gov ↗